{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T01:29:50Z","timestamp":1794274190852,"version":"4.9.0"},"reference-count":127,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T00:00:00Z","timestamp":1773878400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T00:00:00Z","timestamp":1773878400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Infection"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1007\/s15010-026-02770-6","type":"journal-article","created":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T01:42:05Z","timestamp":1773884525000},"page":"1677-1699","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Advancing global malaria control: therapeutic strategies, drug discovery, and formulation innovations"],"prefix":"10.1007","volume":"54","author":[{"given":"Khyatirupa","family":"Sarma","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hrishikesh","family":"Sarma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jitul","family":"Deka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,19]]},"reference":[{"key":"2770_CR1","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanmic.2025.101073","author":"P Venkatesan","year":"2025","unstructured":"Venkatesan P. WHO world malaria report 2024. Lancet Microbe. 2025. https:\/\/doi.org\/10.1016\/j.lanmic.2025.101073.","journal-title":"Lancet Microbe"},{"issue":"1","key":"2770_CR2","doi-asserted-by":"publisher","DOI":"10.1186\/s12936-025-05355-0","volume":"24","author":"C Audibert","year":"2025","unstructured":"Audibert C, Hugo P, Gosling R, Eddis C, Center M, Tchouatieu AM. Projected uptake of sulfadoxine\u2013pyrimethamine for perennial malaria chemoprevention in children under 2 years of age in nine sub-Saharan African countries: an epidemiologically-based 5-year forecast analysis. Malar J. 2025;24(1):124. https:\/\/doi.org\/10.1186\/s12936-025-05355-0.","journal-title":"Malar J"},{"issue":"7572","key":"2770_CR3","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1038\/nature15535","volume":"526","author":"S Bhatt","year":"2015","unstructured":"Bhatt S, Weiss DJ, Cameron E, Bisanzio D, Mappin B, Dalrymple U, et al. The effect of malaria control on Plasmodium falciparum in Africa between 2000 and 2015. Nature. 2015;526(7572):207\u201311. https:\/\/doi.org\/10.1038\/nature15535.","journal-title":"Nature"},{"key":"2770_CR4","unstructured":"Amakrane K, Rosengaertner S, Simpson NP, de Sherbinin A, Linekar J, Horwood C, Jones B, Cottier F, Adamo S, Mills B, Yetman G. African shifts: the Africa climate mobility report, addressing climate-forced migration & displacement."},{"issue":"6","key":"2770_CR5","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pgph.0004592","volume":"5","author":"AJ DePina","year":"2025","unstructured":"DePina AJ, Lima GL, Moreira AL, Niang EH, Garcia KK. Imported malaria in Cabo Verde (2010\u20132024): risks to post-elimination stability. PLOS Glob Public Health. 2025;5(6):e0004592. https:\/\/doi.org\/10.1371\/journal.pgph.0004592.","journal-title":"PLOS Glob Public Health"},{"issue":"1","key":"2770_CR6","doi-asserted-by":"publisher","DOI":"10.1111\/aen.70003","volume":"64","author":"N Gyawali","year":"2025","unstructured":"Gyawali N, Russell TL, Burkot TR, Devine GJ. A morphological identification key to the mosquito disease vectors of the Pacific. Aust Entomol. 2025;64(1):e70003. https:\/\/doi.org\/10.1111\/aen.70003.","journal-title":"Aust Entomol"},{"key":"2770_CR7","doi-asserted-by":"publisher","first-page":"152","DOI":"10.9734\/bpi\/capr\/v8\/3373C","volume":"8","author":"P Gupta","year":"2022","unstructured":"Gupta P. Rapid diagnostic tests for malaria: challenges and future prospects, a brief review. Chall Adv Pharm Res. 2022;8:152\u201362. https:\/\/doi.org\/10.9734\/bpi\/capr\/v8\/3373C.","journal-title":"Chall Adv Pharm Res"},{"issue":"2","key":"2770_CR8","doi-asserted-by":"publisher","first-page":"402","DOI":"10.4236\/ojepi.2025.152026","volume":"15","author":"WD Ouedraogo","year":"2025","unstructured":"Ouedraogo WD, Kabore A, Hien A, Somda S, Sie A, Drabo M, et al. Good practices to malaria elimination in countries from 2016 to 2023: a systematic literature review. Open J Epidemiol. 2025;15(2):402\u201320. https:\/\/doi.org\/10.4236\/ojepi.2025.152026.","journal-title":"Open J Epidemiol"},{"key":"2770_CR9","doi-asserted-by":"publisher","DOI":"10.1101\/2024.09.30.24314608","author":"R Budodo","year":"2024","unstructured":"Budodo R, Bakari C, Mandai SS, Seth MD, Francis F, Chacha GA, et al. Performance of rapid diagnostic tests microscopy and qPCR for detection of parasites among community members with or without symptoms of malaria in villages with high levels of artemisinin partial resistance in North-western Tanzania. medRxiv. 2024. https:\/\/doi.org\/10.1101\/2024.09.30.24314608.","journal-title":"medRxiv"},{"key":"2770_CR10","doi-asserted-by":"publisher","DOI":"10.2147\/IDR.S375197","author":"S Nikiema","year":"2022","unstructured":"Nikiema S, Soulama I, Sombi\u00e9 S, Tchouatieu AM, Serm\u00e9 SS, Henry NB, et al. Seasonal malaria chemoprevention implementation: effect on malaria incidence and immunity in a context of expansion of P. falciparum resistant genotypes with potential reduction of the effectiveness in Sub-Saharan Africa. Infect Drug Res. 2022. https:\/\/doi.org\/10.2147\/IDR.S375197.","journal-title":"Infect Drug Res"},{"issue":"1","key":"2770_CR11","doi-asserted-by":"publisher","DOI":"10.4269\/ajtmh.23-0481","volume":"110","author":"J Thwing","year":"2023","unstructured":"Thwing J, Williamson J, Cavros I, Gutman JR. Systematic review and meta-analysis of seasonal malaria chemoprevention. Am J Trop Med Hyg. 2023;110(1):20. https:\/\/doi.org\/10.4269\/ajtmh.23-0481.","journal-title":"Am J Trop Med Hyg"},{"issue":"1","key":"2770_CR12","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1186\/s12936-025-05630-0","volume":"24","author":"S Sen","year":"2025","unstructured":"Sen S, Schellenberg D, Penny MA. Rethinking a hybrid malaria chemoprevention delivery strategy for children in sub-perennial settings: a modelling study integrating age-and seasonally-targeted delivery. Malar J. 2025;24(1):419.","journal-title":"Malar J"},{"key":"2770_CR13","doi-asserted-by":"publisher","DOI":"10.1016\/j.tmaid.2025.102908","volume":"17","author":"A Elgadi","year":"2025","unstructured":"Elgadi A, Noorallah T, Abdelazim E, Altraifi S, Altraifi H, Elhaj A, et al. Intermittent preventive treatment regimens for malaria in HIV-positive pregnant women: systematic review and meta-analysis of clinical trials. Travel Med Infect Dis. 2025;17:102908.","journal-title":"Travel Med Infect Dis"},{"key":"2770_CR14","doi-asserted-by":"publisher","DOI":"10.1186\/1475-2875-10-144","volume":"10","author":"J Achan","year":"2011","unstructured":"Achan J, Talisuna AO, Erhart A, Yeka A, Tibenderana JK, Baliraine FN, et al. Quinine, an old anti-malarial drug in a modern world: role in the treatment of malaria. Malar J. 2011;10:144. https:\/\/doi.org\/10.1186\/1475-2875-10-144.","journal-title":"Malar J"},{"key":"2770_CR15","doi-asserted-by":"publisher","first-page":"172","DOI":"10.4997\/JRCPE.2010.216","volume":"40","author":"AR Butler","year":"2010","unstructured":"Butler AR, Khan S, Ferguson E. A brief history of malaria chemotherapy. J R Coll Physicians Edinb. 2010;40:172\u20137. https:\/\/doi.org\/10.4997\/JRCPE.2010.216.","journal-title":"J R Coll Physicians Edinb"},{"key":"2770_CR16","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1128\/cmr.15.4.595-612.2002","volume":"15","author":"FEG Cox","year":"2002","unstructured":"Cox FEG. History of human parasitology. Clin Microbiol Rev. 2002;15:595\u2013612. https:\/\/doi.org\/10.1128\/cmr.15.4.595-612.2002.","journal-title":"Clin Microbiol Rev"},{"key":"2770_CR17","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1016\/S0140-6736(20)30552-3","volume":"395","author":"RW Van der Pluijm","year":"2020","unstructured":"Van der Pluijm RW, Tripura R, Hoglund RM, Pyae Pjyo A, Lek D, Islam UI, et al. Triple artemisinin-based combination therapies versus artemisinin-based combination therapies for uncomplicated Plasmodium falciparum malaria: a multicentre, open-label, randomised clinical trial. Lancet. 2020;395:1345\u201360. https:\/\/doi.org\/10.1016\/S0140-6736(20)30552-3.","journal-title":"Lancet"},{"issue":"1","key":"2770_CR18","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1080\/17460441.2020.1804357","volume":"16","author":"LP de Carvalho","year":"2021","unstructured":"de Carvalho LP, Kreidenweiss A, Held J. The preclinical discovery and development of rectal artesunate for the treatment of malaria in young children: a review of the evidence. Expert Opin Drug Discov. 2021;16(1):13\u201322.","journal-title":"Expert Opin Drug Discov"},{"issue":"12","key":"2770_CR19","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1038\/s41579-024-01065-7","volume":"22","author":"PE Duffy","year":"2024","unstructured":"Duffy PE, Gorres JP, Healy SA, Fried M. Malaria vaccines: a new era of prevention and control. Nat Rev Microbiol. 2024;22(12):756\u201372. https:\/\/doi.org\/10.1038\/s41579-024-01065-7.","journal-title":"Nat Rev Microbiol"},{"key":"2770_CR20","doi-asserted-by":"publisher","unstructured":"Adukpo S. Malaria vaccine development and associated challenges. Preventing Malaria \u2013 molecular approaches in breaking the cycle [Working Title]. IntechOpen; 2024. https:\/\/doi.org\/10.5772\/intechopen.115131","DOI":"10.5772\/intechopen.115131"},{"key":"2770_CR21","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1001\/jama.2022.12366","volume":"328","author":"JP Daily","year":"2022","unstructured":"Daily JP, Minuti A, Khan N. Diagnosis, treatment, and prevention of malaria in the US: a review. JAMA. 2022;328:460\u201371. https:\/\/doi.org\/10.1001\/jama.2022.12366.","journal-title":"JAMA"},{"issue":"2","key":"2770_CR22","doi-asserted-by":"publisher","first-page":"93","DOI":"10.3347\/kjp.2009.47.2.93","volume":"47","author":"N Tangpukdee","year":"2009","unstructured":"Tangpukdee N, Duangdee C, Wilairatana P, Krudsood S. Malaria diagnosis: a brief review. Korean J Parasitol. 2009;47(2):93. https:\/\/doi.org\/10.3347\/kjp.2009.47.2.93.","journal-title":"Korean J Parasitol"},{"issue":"13","key":"2770_CR23","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.914598","volume":"19","author":"K Pohl","year":"2022","unstructured":"Pohl K, Cockburn IA. Innate immunity to malaria: the good, the bad and the unknown. Front Immunol. 2022;19(13):914598.","journal-title":"Front Immunol"},{"issue":"2","key":"2770_CR24","doi-asserted-by":"publisher","first-page":"477","DOI":"10.4269\/ajtmh.21-0196","volume":"105","author":"T Nordmann","year":"2021","unstructured":"Nordmann T, Davi SD, Ramharter M, Mischlinger J. Quantification of the proportion of unfavorable clinical outcomes among imported malaria patients according to the degree of semi-immunity on population level: an ecological study. Am J Trop Med Hyg. 2021;105(2):477.","journal-title":"Am J Trop Med Hyg"},{"key":"2770_CR25","doi-asserted-by":"publisher","first-page":"3","DOI":"10.4314\/thrb.v14i1.2","volume":"14","author":"A Kalinga","year":"2012","unstructured":"Kalinga A, Mayige M, Kagaruki G, et al. Clinical manifestations and outcomes of severe malaria among children admitted at Rungwe and Kyela district hospitals in south-western Tanzania. Tanzan J Health Res. 2012;14:3\u20138. https:\/\/doi.org\/10.4314\/thrb.v14i1.2.","journal-title":"Tanzan J Health Res"},{"key":"2770_CR26","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1186\/s12916-017-0906-5","volume":"15","author":"P Sypniewska","year":"2017","unstructured":"Sypniewska P, Duda JF, Locatelli I, Althaus CR, Althaus F, Genton B. Clinical and laboratory predictors of death in African children with features of severe malaria: a systematic review and meta-analysis. BMC Med. 2017;15:147. https:\/\/doi.org\/10.1186\/s12916-017-0906-5.","journal-title":"BMC Med"},{"issue":"9918","key":"2770_CR27","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1016\/S0140-6736(13)60024-0","volume":"383","author":"NJ White","year":"2014","unstructured":"White NJ, et al. Malaria. Lancet. 2014;383(9918):723\u201335.","journal-title":"Lancet"},{"key":"2770_CR28","doi-asserted-by":"publisher","DOI":"10.1186\/1475-2875-7-199","volume":"7","author":"B Ngasala","year":"2008","unstructured":"Ngasala B, Mubi M, Warsame M, Petzold MG, Massele AY, Gustafsson LL, et al. Impact of training in clinical and microscopy diagnosis of childhood malaria on anti-malarial drug prescription and health outcome at primary health care level in Tanzania: a randomized controlled trial. Malar J. 2008;7:199. https:\/\/doi.org\/10.1186\/1475-2875-7-199.","journal-title":"Malar J"},{"key":"2770_CR29","doi-asserted-by":"publisher","first-page":"108","DOI":"10.4103\/0377-4929.40419","volume":"51","author":"PL Bhandari","year":"2008","unstructured":"Bhandari PL, Raghuveer CV, Rajeev A, Bhandari PD. Comparative study of peripheral blood smear, quantitative buffy coat and modified centrifuged blood smear in malaria diagnosis. Indian J Pathol Microbiol. 2008;51:108\u201312. https:\/\/doi.org\/10.4103\/0377-4929.40419.","journal-title":"Indian J Pathol Microbiol"},{"key":"2770_CR30","doi-asserted-by":"publisher","first-page":"631","DOI":"10.2147\/tcrm.s2809","volume":"4","author":"H Tagbor","year":"2008","unstructured":"Tagbor H, Bruce J, Browne E, Greenwood B, Chandramohan D. Performance of the OptiMAL dipstick in the diagnosis of malaria infection in pregnancy. Ther Clin Risk Manag. 2008;4:631\u20136. https:\/\/doi.org\/10.2147\/tcrm.s2809.","journal-title":"Ther Clin Risk Manag"},{"key":"2770_CR31","first-page":"93","volume":"49","author":"N Zerpa","year":"2008","unstructured":"Zerpa N, Pab\u00f3n R, Wide A, Gavidia M, Medina M, C\u00e1ceres JL, et al. Evaluation of the OptiMAL test for diagnosis of malaria in Venezuela. Invest Clin. 2008;49:93\u2013101.","journal-title":"Invest Clin"},{"key":"2770_CR32","doi-asserted-by":"publisher","first-page":"670","DOI":"10.4269\/ajtmh.2008.79.670","volume":"79","author":"A Ratsimbasoa","year":"2008","unstructured":"Ratsimbasoa A, Fanazava L, Radrianjafy R, Ramilijaona J, Rafanomezantsoa H, M\u00e9nard D. Evaluation of two new immunochromatographic assays for diagnosis of malaria. Am J Trop Med Hyg. 2008;79:670\u20132.","journal-title":"Am J Trop Med Hyg"},{"issue":"5","key":"2770_CR33","doi-asserted-by":"publisher","first-page":"768","DOI":"10.3390\/diagnostics11050768","volume":"11","author":"MJ Kavanaugh","year":"2021","unstructured":"Kavanaugh MJ, Azzam SE, Rockabrand DM. Malaria rapid diagnostic tests: literary review and recommendation for a quality assurance, quality control algorithm. Diagnostics. 2021;11(5):768.","journal-title":"Diagnostics"},{"issue":"5","key":"2770_CR34","doi-asserted-by":"publisher","first-page":"1902","DOI":"10.4269\/ajtmh.20-0485","volume":"103","author":"GS Alemayehu","year":"2020","unstructured":"Alemayehu GS, Lopez K, Dieng CC, Lo E, Janies D, Golassa L. Evaluation of PfHRP2 and PfLDH malaria rapid diagnostic test performance in Assosa Zone, Ethiopia. Am J Trop Med Hyg. 2020;103(5):1902.","journal-title":"Am J Trop Med Hyg"},{"issue":"3","key":"2770_CR35","doi-asserted-by":"publisher","first-page":"385","DOI":"10.4269\/ajtmh.2008.79.385","volume":"79","author":"ML McMorrow","year":"2008","unstructured":"McMorrow ML, Masanja MI, Abdulla SM, Kahigwa E, Kachur SP. Challenges in routine implementation and quality control of rapid diagnostic tests for malaria-Rufiji District, Tanzania. Am J Trop Med Hyg. 2008;79(3):385\u201390.","journal-title":"Am J Trop Med Hyg"},{"key":"2770_CR36","doi-asserted-by":"publisher","DOI":"10.1186\/1475-2875-7-118","volume":"7","author":"T Endeshaw","year":"2008","unstructured":"Endeshaw T, Gebre T, Ngondi J, Graves PM, Shargie EB, Ejigsemahu Y, et al. Evaluation of light microscopy and rapid diagnostic test for the detection of malaria under operational field conditions: a household survey in Ethiopia. Malar J. 2008;7:118. https:\/\/doi.org\/10.1186\/1475-2875-7-118.","journal-title":"Malar J"},{"key":"2770_CR37","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1128\/JCM.02110-07","volume":"46","author":"SW Lee","year":"2008","unstructured":"Lee SW, Jeon K, Jeon BR, Park I. Rapid diagnosis of vivax malaria by the SD Bioline Malaria Antigen test when thrombocytopenia is present. J Clin Microbiol. 2008;46:939\u201342. https:\/\/doi.org\/10.1128\/JCM.02110-07.","journal-title":"J Clin Microbiol"},{"key":"2770_CR38","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1186\/1475-2875-7-160","volume":"7","author":"SA Harvey","year":"2008","unstructured":"Harvey SA, Jennings L, Chinyama M, Masaninga F, Mulholland K, Bell DR. Improving community health worker use of malaria rapid diagnostic tests in Zambia: package instructions, job aid and job aid-plus-training. Malar J. 2008;7:160. https:\/\/doi.org\/10.1186\/1475-2875-7-160.","journal-title":"Malar J"},{"key":"2770_CR39","doi-asserted-by":"publisher","first-page":"850","DOI":"10.4269\/ajtmh.2005.73.850","volume":"73","author":"H Swan","year":"2005","unstructured":"Swan H, Sloan L, Muyombwe A, Chavalitshewinkoon-Petmitr P, Krudsood S, Leowattana W, et al. Evaluation of a real-time polymerase chain reaction assay for the diagnosis of malaria in patients from Thailand. Am J Trop Med Hyg. 2005;73:850\u20134.","journal-title":"Am J Trop Med Hyg"},{"key":"2770_CR40","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmi.2025.03.009","author":"DG Okwu","year":"2025","unstructured":"Okwu DG, Manego RZ, Duparc S, Kremsner PG, Ramharter M, Mombo-Ngoma G. The non-artemisinin antimalarial drugs under development: a review. Clin Microbiol Infect. 2025. https:\/\/doi.org\/10.1016\/j.cmi.2025.03.009.","journal-title":"Clin Microbiol Infect"},{"key":"2770_CR41","doi-asserted-by":"publisher","first-page":"1976","DOI":"10.1016\/S0140-6736(20)32677-5","volume":"396","author":"J Wang","year":"2021","unstructured":"Wang J, Xu C, Wong YK, Ma N, Liao FL, Jiang T, et al. Triple artemisinin-based combination therapies for malaria: proceed with caution. Lancet. 2021;396:1976. https:\/\/doi.org\/10.1016\/S0140-6736(20)32677-5.","journal-title":"Lancet"},{"issue":"Suppl. 1","key":"2770_CR42","first-page":"4","volume":"32","author":"DC Warhurst","year":"2001","unstructured":"Warhurst DC, Adagu IS, Beck HP, Duraisingh MT, Kirby GC, von Seidlein L, et al. Mode of action of artemether lumefantrine (COARTEM): the sole, fixed, oral ADCC and its role in combatting multidrug resistance. Southeast Asian J Trop Med Public Health. 2001;32(Suppl. 1):4\u20138.","journal-title":"Southeast Asian J Trop Med Public Health."},{"key":"2770_CR43","unstructured":"Liver Tox: clinical and research Information on drug-induced liver injury. Amodiaquine. National Institute of Diabetes and Digestive and Kidney Diseases. 2017."},{"issue":"1","key":"2770_CR44","doi-asserted-by":"publisher","first-page":"4568","DOI":"10.1038\/s41467-023-39914-3","volume":"14","author":"TD Nguyen","year":"2023","unstructured":"Nguyen TD, Gao B, Amaratunga C, Dhorda M, Tran TN, White NJ, et al. Preventing antimalarial drug resistance with triple artemisinin-based combination therapies. Nat Commun. 2023;14(1):4568. https:\/\/doi.org\/10.1038\/s41467-023-39914-3.","journal-title":"Nat Commun"},{"issue":"10472","key":"2770_CR45","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/S0140-6736(24)02706-5","volume":"405","author":"R Martinez-Vega","year":"2025","unstructured":"Martinez-Vega R, Ishengoma DS, Gosling R, Rosenthal PJ, Dondorp A, Barnes KI, et al. Regional action needed to halt antimalarial drug resistance in Africa. Lancet. 2025;405(10472):7\u201310. https:\/\/doi.org\/10.1016\/S0140-6736(24)02706-5.","journal-title":"Lancet"},{"issue":"3","key":"2770_CR46","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1007\/s44197-024-00228-2","volume":"14","author":"J Li","year":"2024","unstructured":"Li J, Docile HJ, Fisher D, Pronyuk K, Zhao L. Current status of malaria control and elimination in Africa: epidemiology, diagnosis, treatment, progress and challenges. J Epidemiol Glob Health. 2024;14(3):561\u201379. https:\/\/doi.org\/10.1007\/s44197-024-00228-2.","journal-title":"J Epidemiol Glob Health"},{"key":"2770_CR47","unstructured":"Plus ED. E-DRUG: Press release: GSK submits US regulatory application for single-dose tafenoquine for Plasmodium vivax malaria. https:\/\/talk.edrugplus.org\/t\/e-drug-press-release-gsk-submits-us-regulatory-application-for-single-dose-tafenoquine-for-plasmodium-vivax-malaria\/44054."},{"issue":"5","key":"2770_CR48","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1111\/cbdd.13484","volume":"93","author":"S Rout","year":"2019","unstructured":"Rout S, Mahapatra RK. Plasmodium falciparum: multidrug resistance. Chem Biol Drug Des. 2019;93(5):737\u201359. https:\/\/doi.org\/10.1111\/cbdd.13484.","journal-title":"Chem Biol Drug Des"},{"issue":"1","key":"2770_CR49","doi-asserted-by":"publisher","DOI":"10.1186\/1475-2875-13-286","volume":"13","author":"C Smith Gueye","year":"2014","unstructured":"Smith Gueye C, Newby G, Hwang J, Phillips AA, Whittaker M, MacArthur JR, et al. The challenge of artemisinin resistance can only be met by eliminating Plasmodium falciparum malaria across the Greater Mekong subregion. Malar J. 2014;13(1):286. https:\/\/doi.org\/10.1186\/1475-2875-13-286.","journal-title":"Malar J"},{"issue":"6","key":"2770_CR50","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.4269\/ajtmh.19-0379","volume":"101","author":"MR Hassett","year":"2019","unstructured":"Hassett MR, Roepe PD. Origin and spread of evolving artemisinin-resistant Plasmodium falciparum malarial parasites in Southeast Asia. Am J Trop Med Hyg. 2019;101(6):1204. https:\/\/doi.org\/10.4269\/ajtmh.19-0379.","journal-title":"Am J Trop Med Hyg"},{"issue":"1","key":"2770_CR51","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1093\/femsre\/fuw037","volume":"41","author":"CJ Woodrow","year":"2017","unstructured":"Woodrow CJ, White NJ. The clinical impact of artemisinin resistance in Southeast Asia and the potential for future spread. FEMS Microbiol Rev. 2017;41(1):34\u201348. https:\/\/doi.org\/10.1093\/femsre\/fuw037.","journal-title":"FEMS Microbiol Rev"},{"issue":"9","key":"2770_CR52","doi-asserted-by":"publisher","first-page":"e591","DOI":"10.1016\/S1473-3099(24)00141-5","volume":"24","author":"PJ Rosenthal","year":"2024","unstructured":"Rosenthal PJ, Asua V, Bailey JA, Conrad MD, Ishengoma DS, Kamya MR, et al. The emergence of artemisinin partial resistance in Africa: how do we respond? Lancet Infect Dis. 2024;24(9):e591-600. https:\/\/doi.org\/10.1016\/S1473-3099(24)00141-5.","journal-title":"Lancet Infect Dis"},{"issue":"3","key":"2770_CR53","doi-asserted-by":"publisher","DOI":"10.3390\/pathogens13030182","volume":"13","author":"MF Wiser","year":"2024","unstructured":"Wiser MF. The digestive vacuole of the malaria parasite: a specialized lysosome. Pathogens. 2024;13(3):182. https:\/\/doi.org\/10.3390\/pathogens13030182.","journal-title":"Pathogens"},{"issue":"3","key":"2770_CR54","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1021\/cb4008953","volume":"9","author":"CA Hrycyna","year":"2014","unstructured":"Hrycyna CA, Summers RL, Lehane AM, Pires MM, Namanja H, Bohn K, et al. Quinine dimers are potent inhibitors of the Plasmodium falciparum chloroquine resistance transporter and are active against quinoline-resistant P. falciparum. ACS Chem Biol. 2014;9(3):722\u201330. https:\/\/doi.org\/10.1021\/cb4008953.","journal-title":"ACS Chem Biol"},{"key":"2770_CR55","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1124\/mol.61.1.35","volume":"61","author":"RA Cooper","year":"2002","unstructured":"Cooper RA, Ferdig MT, Su XZ, Ursos LM, Mu J, et al. Alternative mutations at position 76 of the vacuolar transmembrane protein PfCRT are associated with chloroquine resistance and unique stereospecific quinine and quinidine responses in Plasmodium falciparum. Mol Pharmacol. 2002;61:35\u201342. https:\/\/doi.org\/10.1124\/mol.61.1.35.","journal-title":"Mol Pharmacol"},{"issue":"4","key":"2770_CR56","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1093\/infdis\/jix334","volume":"216","author":"S Agrawal","year":"2017","unstructured":"Agrawal S, Moser KA, Morton L, Cummings MP, Parihar A, Dwivedi A, et al. Association of a novel mutation in the Plasmodium falciparum chloroquine resistance transporter with decreased piperaquine sensitivity. J Infect Dis. 2017;216(4):468\u201376. https:\/\/doi.org\/10.1093\/infdis\/jix334.","journal-title":"J Infect Dis"},{"issue":"1","key":"2770_CR57","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1146\/annurev-micro-020518-115546","volume":"74","author":"KJ Wicht","year":"2020","unstructured":"Wicht KJ, Mok S, Fidock DA. Molecular mechanisms of drug resistance in Plasmodium falciparum malaria. Annu Rev Microbiol. 2020;74(1):431\u201354. https:\/\/doi.org\/10.1146\/annurev-micro-020518-115546.","journal-title":"Annu Rev Microbiol"},{"key":"2770_CR58","doi-asserted-by":"publisher","DOI":"10.1016\/j.tox.2021.152995","volume":"464","author":"DK Ghosh","year":"2021","unstructured":"Ghosh DK, Kumar A, Ranjan A. Cellular targets of mefloquine. Toxicology. 2021;464:152995. https:\/\/doi.org\/10.1016\/j.tox.2021.152995.","journal-title":"Toxicology"},{"issue":"5","key":"2770_CR59","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pbio.3001616","volume":"20","author":"SH Shafik","year":"2022","unstructured":"Shafik SH, Richards SN, Corry B, Martin RE. Mechanistic basis for multidrug resistance and collateral drug sensitivity conferred to the malaria parasite by polymorphisms in PfMDR1 and PfCRT. PLoS Biol. 2022;20(5):e3001616. https:\/\/doi.org\/10.1371\/journal.pbio.3001616.","journal-title":"PLoS Biol"},{"issue":"9","key":"2770_CR60","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0023875","volume":"6","author":"PE Ferreira","year":"2011","unstructured":"Ferreira PE, Holmgren G, Veiga MI, Uhlen P, Kaneko A, Gil JP. PfMDR1: mechanisms of transport modulation by functional polymorphisms. PLoS ONE. 2011;6(9):e23875. https:\/\/doi.org\/10.1371\/journal.pone.0023875.","journal-title":"PLoS ONE"},{"issue":"14","key":"2770_CR61","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1016\/j.meegid.2012.12.014","volume":"1","author":"S Pirahmadi","year":"2013","unstructured":"Pirahmadi S, Zakeri S, Afsharpad M, Djadid ND. Mutation analysis in pfmdr1 and pfmrp1 as potential candidate genes for artemisinin resistance in Plasmodium falciparum clinical isolates 4 years after implementation of artemisinin combination therapy in Iran. Infect Genet Evol. 2013;1(14):327\u201334. https:\/\/doi.org\/10.1016\/j.meegid.2012.12.014.","journal-title":"Infect Genet Evol"},{"key":"2770_CR62","first-page":"560","volume-title":"Biochemical protozoology","author":"RD Walter","year":"1991","unstructured":"Walter RD. Folate metabolism as a target for chemotherapy of malaria. In: Coombs GH, North MJ, editors. Biochemical protozoology. London: Taylor Francis; 1991. p. 560\u20138."},{"key":"2770_CR63","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijbiomac.2025.143325","volume":"18","author":"D Sanyal","year":"2025","unstructured":"Sanyal D, Shivram A, Pandey D, Banerjee S, Uversky VN, Muzata D, et al. Mapping dihydropteroate synthase evolvability through identification of a novel evolutionarily critical substructure. Int J Biol Macromol. 2025;18:143325. https:\/\/doi.org\/10.1016\/j.ijbiomac.2025.143325.","journal-title":"Int J Biol Macromol"},{"issue":"10","key":"2770_CR64","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2020.600112","volume":"26","author":"BK Torrevillas","year":"2020","unstructured":"Torrevillas BK, Garrison SM, McKeeken AJ, Patel D, Van Leuven JT, Dizon NI, et al. Plasmodium falciparum DHFR and DHPS mutations are associated with HIV-1 co-infection and a novel DHPS mutation I504T is identified in Western Kenya. Front Cell Infect Microbiol. 2020;26(10):600112. https:\/\/doi.org\/10.3389\/fcimb.2020.600112.","journal-title":"Front Cell Infect Microbiol"},{"issue":"3","key":"2770_CR65","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0007223","volume":"13","author":"DW Juma","year":"2019","unstructured":"Juma DW, Muiruri P, Yuhas K, John-Stewart G, Ottichilo R, Waitumbi J, et al. The prevalence and antifolate drug resistance profiles of Plasmodium falciparum in study participants randomized to discontinue or continue cotrimoxazole prophylaxis. PLoS Negl Trop Dis. 2019;13(3):e0007223. https:\/\/doi.org\/10.1371\/journal.pntd.0007223.","journal-title":"PLoS Negl Trop Dis"},{"issue":"25","key":"2770_CR66","doi-asserted-by":"publisher","first-page":"13944","DOI":"10.1073\/pnas.94.25.13944","volume":"94","author":"T Triglia","year":"1997","unstructured":"Triglia T, Menting JG, Wilson C, Cowman AF. Mutations in dihydropteroate synthase are responsible for sulfone and sulfonamide resistance in Plasmodium falciparum. Proc Natl Acad Sci. 1997;94(25):13944\u20139. https:\/\/doi.org\/10.1073\/pnas.94.25.13944.","journal-title":"Proc Natl Acad Sci"},{"issue":"11","key":"2770_CR67","doi-asserted-by":"publisher","first-page":"3883","DOI":"10.1128\/aac.00431-08","volume":"52","author":"E Ochong","year":"2008","unstructured":"Ochong E, Bell DJ, Johnson DJ, D\u2019Alessandro U, Mulenga M, Muangnoicharoen S, et al. Plasmodium falciparum strains harboring dihydrofolate reductase with the I164L mutation are absent in Malawi and Zambia even under antifolate drug pressure. Antimicrob Agents Chemother. 2008;52(11):3883\u20138. https:\/\/doi.org\/10.1128\/aac.00431-08.","journal-title":"Antimicrob Agents Chemother"},{"issue":"4","key":"2770_CR68","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1073\/pnas.94.4.1124","volume":"94","author":"W Sirawaraporn","year":"1997","unstructured":"Sirawaraporn W, Sathitkul T, Sirawaraporn R, Yuthavong Y, Santi DV. Antifolate-resistant mutants of Plasmodium falciparum dihydrofolate reductase. Proc Natl Acad Sci. 1997;94(4):1124\u20139. https:\/\/doi.org\/10.1073\/pnas.94.4.1124.","journal-title":"Proc Natl Acad Sci"},{"issue":"46","key":"2770_CR69","doi-asserted-by":"publisher","first-page":"18796","DOI":"10.1073\/pnas.1116162108","volume":"108","author":"S Mharakurwa","year":"2011","unstructured":"Mharakurwa S, Kumwenda T, Mkulama MA, Musapa M, Chishimba S, Shiff CJ, et al. Malaria antifolate resistance with contrasting Plasmodium falciparum dihydrofolate reductase (DHFR) polymorphisms in humans and Anopheles mosquitoes. Proc Natl Acad Sci. 2011;108(46):18796\u2013801. https:\/\/doi.org\/10.1073\/pnas.1116162108.","journal-title":"Proc Natl Acad Sci"},{"issue":"6","key":"2770_CR70","doi-asserted-by":"publisher","first-page":"1244","DOI":"10.1021\/jm010131q","volume":"45","author":"B Tarnchompoo","year":"2002","unstructured":"Tarnchompoo B, Sirichaiwat C, Phupong W, Intaraudom C, Sirawaraporn W, Kamchonwongpaisan S, et al. Development of 2, 4-Diaminopyrimidines as antimalarials based on inhibition of the S108N and C59R+ S108N mutants of dihydrofolate reductase from pyrimethamine-resistant Plasmodium falciparum. J Med Chem. 2002;45(6):1244\u201352. https:\/\/doi.org\/10.1021\/jm010131q.","journal-title":"J Med Chem"},{"issue":"12","key":"2770_CR71","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1021\/acsmedchemlett.8b00389","volume":"9","author":"B Tarnchompoo","year":"2018","unstructured":"Tarnchompoo B, Chitnumsub P, Jaruwat A, Shaw PJ, Vanichtanankul J, Poen S, et al. Hybrid inhibitors of malarial dihydrofolate reductase with dual binding modes that can forestall resistance. ACS Med Chem Lett. 2018;9(12):1235\u201340. https:\/\/doi.org\/10.1021\/acsmedchemlett.8b00389.","journal-title":"ACS Med Chem Lett"},{"issue":"9","key":"2770_CR72","doi-asserted-by":"publisher","first-page":"223","DOI":"10.3390\/tropicalmed9090223","volume":"9","author":"D Zheng","year":"2024","unstructured":"Zheng D, Liu T, Yu S, Liu Z, Wang J, Wang Y. Antimalarial mechanisms and resistance status of artemisinin and its derivatives. Trop Med Infect Dis. 2024;9(9):223. https:\/\/doi.org\/10.3390\/tropicalmed9090223.","journal-title":"Trop Med Infect Dis"},{"issue":"7549","key":"2770_CR73","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1038\/nature14412","volume":"520","author":"A Mbengue","year":"2015","unstructured":"Mbengue A, Bhattacharjee S, Pandharkar T, Liu H, Estiu G, Stahelin RV, et al. A molecular mechanism of artemisinin resistance in Plasmodium falciparum malaria. Nature. 2015;520(7549):683\u20137. https:\/\/doi.org\/10.1038\/nature14412.","journal-title":"Nature"},{"issue":"12","key":"2770_CR74","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1016\/j.pt.2023.09.011","volume":"39","author":"K Pandit","year":"2023","unstructured":"Pandit K, Surolia N, Bhattacharjee S, Karmodiya K. The many paths to artemisinin resistance in Plasmodium falciparum. Trends Parasitol. 2023;39(12):1060\u201373. https:\/\/doi.org\/10.1016\/j.pt.2023.09.011.","journal-title":"Trends Parasitol"},{"issue":"51","key":"2770_CR75","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijmmb.2024.100691","volume":"1","author":"K Verma","year":"2024","unstructured":"Verma K, Singh Y, Kamaraj B, Sharma P, Schneider KA, Bharti PK. Mutations in Plasmodium falciparum Kelch13 (PfK13) dysregulates PI3K\/AKT signalling pathway in artemisinin resistance. Indian J Med Microbiol. 2024;1(51):100691. https:\/\/doi.org\/10.1016\/j.ijmmb.2024.100691.","journal-title":"Indian J Med Microbiol"},{"issue":"42","key":"2770_CR76","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.coph.2018.06.003","volume":"1","author":"N Suresh","year":"2018","unstructured":"Suresh N, Haldar K. Mechanisms of artemisinin resistance in Plasmodium falciparum malaria. Curr Opin Pharmacol. 2018;1(42):46\u201354. https:\/\/doi.org\/10.1016\/j.coph.2018.06.003.","journal-title":"Curr Opin Pharmacol"},{"issue":"19","key":"2770_CR77","doi-asserted-by":"publisher","first-page":"5680","DOI":"10.3390\/jcm13195680","volume":"13","author":"M Thellier","year":"2024","unstructured":"Thellier M, Gemegah AA, Tantaoui I. Global fight against malaria: goals and achievements 1900\u20132022. J Clin Med. 2024;13(19):5680. https:\/\/doi.org\/10.3390\/jcm13195680.","journal-title":"J Clin Med"},{"issue":"11","key":"2770_CR78","doi-asserted-by":"publisher","first-page":"1416","DOI":"10.3390\/pharmaceutics16111416","volume":"16","author":"JM Alghamdi","year":"2024","unstructured":"Alghamdi JM, Al-Qahtani AA, Alhamlan FS, Al-Qahtani AA. Recent advances in the treatment of malaria. Pharmaceutics. 2024;16(11):1416. https:\/\/doi.org\/10.3390\/pharmaceutics16111416.","journal-title":"Pharmaceutics"},{"key":"2770_CR79","unstructured":"MMV. MMV\u2019s pipeline of antimalarial drugs. https:\/\/www.mmv.org\/research-development\/mmvs-pipeline-antimalarial-drugs."},{"key":"2770_CR80","unstructured":"Zydus\u202fLifesciences\u202fLimited. A study to determine safety, tolerability, and pharmacokinetics of different orally administered regimens of the combination ZY19489-ferroquine in adult asymptomatic Plasmodium falciparum carriers. Clinical trial NCT05911828. MedPath; 2025 https:\/\/trial.medpath.com\/clinical-trial\/719f3ffa02a2b0a9\/nct05911828-zy19489-ferroquine-plasmodium-falciparum."},{"issue":"4","key":"2770_CR81","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1128\/aac.02181-19","volume":"64","author":"M Rottmann","year":"2020","unstructured":"Rottmann M, Jonat B, Gumpp C, Dhingra SK, Giddins MJ, Yin X, et al. Preclinical antimalarial combination study of M5717, a Plasmodium falciparum elongation factor 2 inhibitor, and pyronaridine, a hemozoin formation inhibitor. Antimicrob Agents Chemother. 2020;64(4):10\u2013128. https:\/\/doi.org\/10.1128\/aac.02181-19.","journal-title":"Antimicrob Agents Chemother"},{"issue":"4","key":"2770_CR82","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1021\/acsinfecdis.1c00640","volume":"8","author":"D Fontinha","year":"2022","unstructured":"Fontinha D, Arez F, Gal IR, Nogueira G, Moita D, Baeurle TH, et al. Pre-erythrocytic activity of M5717 in monotherapy and combination in preclinical Plasmodium infection models. ACS Infect Dis. 2022;8(4):721\u20137. https:\/\/doi.org\/10.1021\/acsinfecdis.1c00640.","journal-title":"ACS Infect Dis"},{"key":"2770_CR83","unstructured":"Merck Healthcare KGaA, Darmstadt, Germany (affiliated with Merck KGaA, Darmstadt, Germany). Phase\u202fIIa proof-of-concept study of M5717-pyronaridine in adults and adolescents with acute uncomplicated Plasmodium falciparum malaria (CAPTURE\u202f1). ClinicalTrials.gov Identifier NCT05689047; 2023\u20132025. https:\/\/clinicaltrials.gov\/study\/NCT05689047."},{"issue":"6","key":"2770_CR84","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1128\/aac.00087-18","volume":"62","author":"AS Dennis","year":"2018","unstructured":"Dennis AS, Lehane AM, Ridgway MC, Holleran JP, Kirk K. Cell swelling induced by the antimalarial KAE609 (cipargamin) and other PfATP4-associated antimalarials. Antimicrob Agents Chemother. 2018;62(6):10\u2013128. https:\/\/doi.org\/10.1128\/aac.00087-18.","journal-title":"Antimicrob Agents Chemother"},{"key":"2770_CR85","doi-asserted-by":"publisher","DOI":"10.1016\/j.tmaid.2020.101765","volume":"36","author":"SA Bouwman","year":"2020","unstructured":"Bouwman SA, Zoleko-Manego R, Renner KC, Schmitt EK, Mombo-Ngoma G, Grobusch MP. The early preclinical and clinical development of cipargamin (KAE609), a novel antimalarial compound. Travel Med Infect Dis. 2020;36:101765. https:\/\/doi.org\/10.1016\/j.tmaid.2020.101765.","journal-title":"Travel Med Infect Dis"},{"key":"2770_CR86","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.101128.4","volume":"13","author":"H Li","year":"2025","unstructured":"Li H, Ji S, Ariefta NR, Galon EM, El-Sayed SA, Do T, et al. Efficacy and mechanism of action of cipargamin as an antibabesial drug candidate. Elife. 2025;13:RP101128. https:\/\/doi.org\/10.7554\/eLife.101128.4.","journal-title":"Elife"},{"issue":"6","key":"2770_CR87","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1016\/S1473-3099(21)00692-7","volume":"22","author":"TJ Peto","year":"2022","unstructured":"Peto TJ, Tripura R, Callery JJ, Lek D, Nghia HD, Nguon C, et al. Triple therapy with artemether\u2013lumefantrine plus amodiaquine versus artemether\u2013lumefantrine alone for artemisinin-resistant, uncomplicated falciparum malaria: an open-label, randomised, multicentre trial. Lancet Infect Dis. 2022;22(6):867\u201378. https:\/\/doi.org\/10.1016\/S1473-3099(21)00692-7.","journal-title":"Lancet Infect Dis"},{"key":"2770_CR88","unstructured":"Medicines for Malaria Venture. Artemether-lumefantrine-amodiaquine fixed-dose combination (FDC). MMV pipeline of antimalarial drugs. 2025. https:\/\/www.mmv.org\/mmv-pipeline-antimalarial-drugs\/artemether-lumefantrine-amodiaquine-fdc."},{"issue":"suppl.","key":"2770_CR89","first-page":"4","volume":"32","author":"DC Warhurst","year":"2001","unstructured":"Warhurst DC, Adagu IS, Beck HP, Duraisingh MT, Kirby GC, von Seidlein L, et al. Mode of action of artemether lumefantrine (COARTEM): the sole, fixed, oral ADCC and its role in combatting multidrug resistance. Southeast Asian J Trop Med Public Health. 2001;32(suppl.):4\u20138.","journal-title":"Southeast Asian J Trop Med Public Health"},{"key":"2770_CR90","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanmic.2024.100966","author":"A Mahamar","year":"2025","unstructured":"Mahamar A, Vanheer LN, Smit MJ, Sanogo K, Sinaba Y, Niambele SM, et al. Artemether\u2013lumefantrine\u2013amodiaquine or artesunate\u2013amodiaquine combined with single low-dose primaquine to reduce Plasmodium falciparum malaria transmission in Ou\u00e9less\u00e9bougou, Mali: a five-arm, phase 2, single-blind, randomised controlled trial. Lancet Microbe. 2025. https:\/\/doi.org\/10.1016\/j.lanmic.2024.100966.","journal-title":"Lancet Microbe"},{"key":"2770_CR91","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmc.2023.117339","volume":"88","author":"T Umumararungu","year":"2023","unstructured":"Umumararungu T, Nkuranga JB, Habarurema G, Nyandwi JB, Mukazayire MJ, Mukiza J, et al. Recent developments in antimalarial drug discovery. Bioorg Med Chem. 2023;88:117339. https:\/\/doi.org\/10.1016\/j.bmc.2023.117339.","journal-title":"Bioorg Med Chem"},{"issue":"1","key":"2770_CR92","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-017-0940-3","volume":"15","author":"F Macintyre","year":"2017","unstructured":"Macintyre F, Adoke Y, Tiono AB, Duong TT, Mombo-Ngoma G, Bouyou-Akotet M, et al. A randomised, double-blind clinical phase II trial of the efficacy, safety, tolerability and pharmacokinetics of a single dose combination treatment with artefenomel and piperaquine in adults and children with uncomplicated Plasmodium falciparum malaria. BMC Med. 2017;15(1):181. https:\/\/doi.org\/10.1186\/s12916-017-0940-3.","journal-title":"BMC Med"},{"issue":"7","key":"2770_CR93","doi-asserted-by":"publisher","first-page":"962","DOI":"10.3390\/ph17070962","volume":"17","author":"F Appetecchia","year":"2024","unstructured":"Appetecchia F, Fabbrizi E, Fiorentino F, Consalvi S, Biava M, Poce G, et al. Transmission-blocking strategies for malaria eradication: recent advances in small-molecule drug development. Pharmaceuticals. 2024;17(7):962.","journal-title":"Pharmaceuticals"},{"issue":"10","key":"2770_CR94","doi-asserted-by":"publisher","first-page":"6209","DOI":"10.1128\/aac.03393-14","volume":"58","author":"FJ Leong","year":"2014","unstructured":"Leong FJ, Li R, Jain JP, Lef\u00e8vre G, Magnusson B, Diagana TT, et al. A first-in-human randomized, double-blind, placebo-controlled, single-and multiple-ascending oral dose study of novel antimalarial Spiroindolone KAE609 (Cipargamin) to assess its safety, tolerability, and pharmacokinetics in healthy adult volunteers. Antimicrob Agents Chemother. 2014;58(10):6209\u201314. https:\/\/doi.org\/10.1128\/aac.03393-14.","journal-title":"Antimicrob Agents Chemother"},{"key":"2770_CR95","doi-asserted-by":"publisher","DOI":"10.1128\/mBio.00696-16","volume":"7","author":"G LaMonte","year":"2016","unstructured":"LaMonte G, Lim MY-X, Wree M, et al. Mutations in the Plasmodium falciparum cyclic amine resistance locus (PfCARL) confer multidrug resistance. MBio. 2016;7:e00696-16. https:\/\/doi.org\/10.1128\/mBio.00696-16.","journal-title":"MBio"},{"key":"2770_CR96","doi-asserted-by":"publisher","DOI":"10.1038\/nmicrobiol.2016.166","volume":"1","author":"MY-X Lim","year":"2016","unstructured":"Lim MY-X, LaMonte G, Lee MCS, et al. UDP-galactose and acetyl-CoA transporters as Plasmodium multidrug resistance genes. Nat Microbiol. 2016;1:16166. https:\/\/doi.org\/10.1038\/nmicrobiol.2016.166.","journal-title":"Nat Microbiol"},{"issue":"9","key":"2770_CR97","doi-asserted-by":"publisher","first-page":"5060","DOI":"10.1128\/aac.02727-13","volume":"58","author":"KL Kuhen","year":"2014","unstructured":"Kuhen KL, Chatterjee AK, Rottmann M, Gagaring K, Borboa R, Buenviaje J, et al. KAF156 is an antimalarial clinical candidate with potential for use in prophylaxis, treatment, and prevention of disease transmission. Antimicrob Agents Chemother. 2014;58(9):5060\u20137. https:\/\/doi.org\/10.1128\/aac.02727-13.","journal-title":"Antimicrob Agents Chemother"},{"key":"2770_CR98","unstructured":"Medicine for Malaria Venture. MMV\u2019s pipeline of antimalarial drugs. 2024. https:\/\/www.mmv.org\/mmv-pipeline-antimalarial-drugs."},{"issue":"11","key":"2770_CR99","doi-asserted-by":"publisher","first-page":"2877","DOI":"10.1093\/jac\/dkae300","volume":"79","author":"J Manaranche","year":"2024","unstructured":"Manaranche J, Laurent M, Tressieres R, Nguyen M, Salim M, Ouji M, et al. In vitro evaluation of ganaplacide\/lumefantrine combination against Plasmodium falciparum in a context of artemisinin resistance. J Antimicrob Chemother. 2024;79(11):2877\u201386. https:\/\/doi.org\/10.1093\/jac\/dkae300.","journal-title":"J Antimicrob Chemother"},{"issue":"10","key":"2770_CR100","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1038\/s41573-023-00772-9","volume":"22","author":"JL Siqueira-Neto","year":"2023","unstructured":"Siqueira-Neto JL, Wicht KJ, Chibale K, Burrows JN, Fidock DA, Winzeler EA. Antimalarial drug discovery: progress and approaches. Nat Rev Drug Discov. 2023;22(10):807\u201326. https:\/\/doi.org\/10.1038\/s41573-023-00772-9.","journal-title":"Nat Rev Drug Discov"},{"issue":"2","key":"2770_CR101","doi-asserted-by":"publisher","DOI":"10.3390\/tropicalmed9020039","volume":"9","author":"L Esser","year":"2024","unstructured":"Esser L, Xia D. Mitochondrial cytochrome bc 1 complex as validated drug target: a structural perspective. Trop Med Infect Dis. 2024;9(2):39. https:\/\/doi.org\/10.3390\/tropicalmed9020039.","journal-title":"Trop Med Infect Dis"},{"issue":"19","key":"2770_CR102","doi-asserted-by":"publisher","first-page":"3326","DOI":"10.2174\/0929867328666210803152419","volume":"29","author":"C Tisnerat","year":"2022","unstructured":"Tisnerat C, Dassonville-Klimpt A, Gosselet F, Sonnet P. Antimalarial drug discovery: from quinine to the most recent promising clinical drug candidates. Curr Med Chem. 2022;29(19):3326\u201365. https:\/\/doi.org\/10.2174\/0929867328666210803152419.","journal-title":"Curr Med Chem"},{"issue":"10","key":"2770_CR103","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1021\/acscentsci.6b00086","volume":"2","author":"AE Williamson","year":"2016","unstructured":"Williamson AE, Ylioja PM, Robertson MN, Antonova-Koch Y, Avery V, Baell JB, et al. Open source drug discovery: highly potent antimalarial compounds derived from the Tres Cantos arylpyrroles. ACS Cent Sci. 2016;2(10):687\u2013701. https:\/\/doi.org\/10.1021\/acscentsci.6b00086.","journal-title":"ACS Cent Sci"},{"key":"2770_CR104","unstructured":"Medicines for Malaria Venture. GSK701. MMV pipeline of antimalarial drugs. MMV. https:\/\/www.mmv.org\/mmv-pipeline-antimalarial-drugs\/gsk701-0."},{"key":"2770_CR105","unstructured":"Medicines for Malaria Venture. MMV awards Project of the Year 2019 to Novartis discovery INE963. MMV. https:\/\/www.mmv.org\/newsroom\/news-resources-search\/mmv-awards-project-year-2019-novartis-discovery-ine963."},{"issue":"5","key":"2770_CR106","doi-asserted-by":"publisher","first-page":"3798","DOI":"10.1021\/acs.jmedchem.1c01995","volume":"65","author":"BR Taft","year":"2022","unstructured":"Taft BR, Yokokawa F, Kirrane T, Mata AC, Huang R, Blaquiere N, et al. Discovery and preclinical pharmacology of INE963, a potent and fast-acting blood-stage antimalarial with a high barrier to resistance and potential for single-dose cures in uncomplicated malaria. J Med Chem. 2022;65(5):3798\u2013813. https:\/\/doi.org\/10.1021\/acs.jmedchem.1c01995.","journal-title":"J Med Chem"},{"issue":"9","key":"2770_CR107","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1128\/aac.00379-17","volume":"61","author":"S Duffy","year":"2017","unstructured":"Duffy S, Sykes ML, Jones AJ, Shelper TB, Simpson M, Lang R, et al. Screening the medicines for malaria Venture pathogen box across multiple pathogens reclassifies starting points for open-source drug discovery. Antimicrob Agents Chemother. 2017;61(9):10\u2013128. https:\/\/doi.org\/10.1128\/aac.00379-17.","journal-title":"Antimicrob Agents Chemother"},{"key":"2770_CR108","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.ijpddr.2023.05.005","volume":"22","author":"H Mbye","year":"2023","unstructured":"Mbye H, Bojang F, Jaiteh FK, Jawara A, Njie B, Correa S, et al. Stepwise in vitro screening of MMV pathogen box compounds against Plasmodium falciparum to identify potent antimalarial candidates. Int J Parasitol Drugs Drug Resist. 2023;22:81\u20137. https:\/\/doi.org\/10.1016\/j.ijpddr.2023.05.005.","journal-title":"Int J Parasitol Drugs Drug Resist"},{"issue":"21","key":"2770_CR109","doi-asserted-by":"publisher","first-page":"9672","DOI":"10.1021\/acs.jmedchem.6b00723","volume":"59","author":"B Baragana","year":"2016","unstructured":"Baragana B, Norcross NR, Wilson C, Porzelle A, Hallyburton I, Grimaldi R, et al. Discovery of a quinoline-4-carboxamide derivative with a novel mechanism of action, multistage antimalarial activity, and potent in vivo efficacy. J Med Chem. 2016;59(21):9672\u201385. https:\/\/doi.org\/10.1021\/acs.jmedchem.6b00723.","journal-title":"J Med Chem"},{"key":"2770_CR110","doi-asserted-by":"publisher","DOI":"10.1038\/s41579-024-01099-x","author":"J Okombo","year":"2024","unstructured":"Okombo J, Fidock DA. Towards next-generation treatment options to combat Plasmodium falciparum malaria. Nat Rev Microbiol. 2024. https:\/\/doi.org\/10.1038\/s41579-024-01099-x.","journal-title":"Nat Rev Microbiol"},{"issue":"387","key":"2770_CR111","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aad9735","volume":"9","author":"T Paquet","year":"2017","unstructured":"Paquet T, Le Manach C, Cabrera DG, Younis Y, Henrich PP, Abraham TS, et al. Antimalarial efficacy of MMV390048, an inhibitor of Plasmodium phosphatidylinositol 4-kinase. Sci Transl Med. 2017;9(387):eaad9735. https:\/\/doi.org\/10.1126\/scitranslmed.aad9735.","journal-title":"Sci Transl Med"},{"issue":"11","key":"2770_CR112","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1128\/aac.01053-18","volume":"62","author":"J Calit","year":"2018","unstructured":"Calit J, Dobrescu I, Gait\u00e1n XA, Borges MH, Ramos MS, Eastman RT, et al. Screening the pathogen box for molecules active against Plasmodium sexual stages using a new nanoluciferase-based transgenic line of P. berghei identifies transmission-blocking compounds. Antimicrob Agents Chemother. 2018;62(11):10\u2013128. https:\/\/doi.org\/10.1128\/aac.01053-18.","journal-title":"Antimicrob Agents Chemother"},{"issue":"5","key":"2770_CR113","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1128\/aac.01802-19","volume":"64","author":"AT Patra","year":"2020","unstructured":"Patra AT, Hingamire T, Belekar MA, Xiong A, Subramanian G, Bozdech Z, et al. Whole-cell phenotypic screening of medicines for malaria Venture pathogen box identifies specific inhibitors of Plasmodium falciparum late-stage development and egress. Antimicrob Agents Chemother. 2020;64(5):10\u2013128. https:\/\/doi.org\/10.1128\/aac.01802-19.","journal-title":"Antimicrob Agents Chemother"},{"key":"2770_CR114","unstructured":"Medicines for Malaria Venture. First-ever long-acting injectable for malaria prevention administered. Geneva: Medicines for Malaria Venture. 2024. https:\/\/www.mmv.org\/newsroom\/news-resources-search\/first-ever-long-acting-injectable-malaria-prevention-administered."},{"issue":"1","key":"2770_CR115","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.ijpharm.2015.09.069","volume":"496","author":"R Fule","year":"2015","unstructured":"Fule R, Dhamecha D, Maniruzzaman M, Khale A, Amin P. Development of hot melt co-formulated antimalarial solid dispersion system in fixed dose form (ARLUMELT): evaluating amorphous state and in vivo performance. Int J Pharm. 2015;496(1):137\u201356. https:\/\/doi.org\/10.1016\/j.ijpharm.2015.09.069.","journal-title":"Int J Pharm"},{"issue":"7","key":"2770_CR116","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1080\/09205063.2020.1870378","volume":"32","author":"R Shah","year":"2021","unstructured":"Shah R, Soni T, Shah U, Suhagia BN, Patel MN, Patel T, et al. Formulation development and characterization of lumefantrine nanosuspension for enhanced antimalarial activity. J Biomater Sci Polym Ed. 2021;32(7):833\u201357. https:\/\/doi.org\/10.1080\/09205063.2020.1870378.","journal-title":"J Biomater Sci Polym Ed"},{"issue":"1","key":"2770_CR117","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1016\/j.ijpharm.2016.07.021","volume":"511","author":"P Prabhu","year":"2016","unstructured":"Prabhu P, Suryavanshi S, Pathak S, Sharma S, Patravale V. Artemether\u2013lumefantrine nanostructured lipid carriers for oral malaria therapy: enhanced efficacy at reduced dose and dosing frequency. Int J Pharm. 2016;511(1):473\u201387. https:\/\/doi.org\/10.1016\/j.ijpharm.2016.07.021.","journal-title":"Int J Pharm"},{"issue":"1","key":"2770_CR118","doi-asserted-by":"publisher","first-page":"123","DOI":"10.3109\/10717544.2014.905883","volume":"23","author":"D Parashar","year":"2016","unstructured":"Parashar D, Np A, Rsr M. Development of artemether and lumefantrine co-loaded nanostructured lipid carriers: physicochemical characterization and in vivo antimalarial activity. Drug Deliv. 2016;23(1):123\u20139. https:\/\/doi.org\/10.3109\/10717544.2014.905883.","journal-title":"Drug Deliv"},{"key":"2770_CR119","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1016\/j.jconrel.2023.08.009","volume":"361","author":"QK Anjani","year":"2023","unstructured":"Anjani QK, Volpe-Zanutto F, Hamid KA, Sabri AH, Moreno-Castellano N, Gait\u00e1n XA, et al. Primaquine and chloroquine nano-sized solid dispersion-loaded dissolving microarray patches for the improved treatment of malaria caused by Plasmodium vivax. J Control Release. 2023;361:385\u2013401. https:\/\/doi.org\/10.1016\/j.jconrel.2023.08.009.","journal-title":"J Control Release"},{"issue":"1","key":"2770_CR120","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1080\/08982104.2017.1410173","volume":"29","author":"K Shakeel","year":"2019","unstructured":"Shakeel K, Raisuddin S, Ali S, Imam SS, Rahman MA, Jain GK, et al. Development and in vitro\/in vivo evaluation of artemether and lumefantrine co-loaded nanoliposomes for parenteral delivery. J Liposome Res. 2019;29(1):35\u201343. https:\/\/doi.org\/10.1080\/08982104.2017.1410173.","journal-title":"J Liposome Res"},{"issue":"4","key":"2770_CR121","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1080\/08982104.2017.1376684","volume":"28","author":"M Thakkar","year":"2018","unstructured":"Thakkar M, Brijesh S. Physicochemical investigation and in vivo activity of anti-malarial drugs co-loaded in Tween 80 niosomes. J Liposome Res. 2018;28(4):315\u201321. https:\/\/doi.org\/10.1080\/08982104.2017.1376684.","journal-title":"J Liposome Res"},{"key":"2770_CR122","doi-asserted-by":"publisher","first-page":"4239","DOI":"10.2147\/IJN.S83402","volume":"30","author":"S Shen","year":"2015","unstructured":"Shen S, Liu SZ, Zhang YS, Du MB, Liang AH, Song LH, et al. Compound antimalarial ethosomal cataplasm: preparation, evaluation, and mechanism of penetration enhancement. Int J Nanomed. 2015;30:4239\u201353. https:\/\/doi.org\/10.2147\/IJN.S83402.","journal-title":"Int J Nanomed"},{"key":"2770_CR123","doi-asserted-by":"publisher","DOI":"10.1016\/j.jddst.2020.102072","volume":"60","author":"A Garg","year":"2020","unstructured":"Garg A, Tomar DS, Bhalala K, Wahajuddin M. Development and investigation of artemether loaded binary solid lipid nanoparticles: physicochemical characterization and in-situ single-pass intestinal permeability. J Drug Deliv Sci Technol. 2020;60:102072. https:\/\/doi.org\/10.1016\/j.jddst.2020.102072.","journal-title":"J Drug Deliv Sci Technol"},{"issue":"1","key":"2770_CR124","doi-asserted-by":"publisher","DOI":"10.1186\/s12936-018-2302-9","volume":"17","author":"JO Muga","year":"2018","unstructured":"Muga JO, Gathirwa JW, Tukulula M, Jura WG. In vitro evaluation of chloroquine-loaded and heparin surface-functionalized solid lipid nanoparticles. Malar J. 2018;17(1):133. https:\/\/doi.org\/10.1186\/s12936-018-2302-9.","journal-title":"Malar J"},{"issue":"3","key":"2770_CR125","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1016\/j.nano.2015.11.017","volume":"12","author":"WN Omwoyo","year":"2016","unstructured":"Omwoyo WN, Melariri P, Gathirwa JW, Oloo F, Mahanga GM, Kalombo L, et al. Development, characterization and antimalarial efficacy of dihydroartemisinin loaded solid lipid nanoparticles. Nanomedicine. 2016;12(3):801\u20139. https:\/\/doi.org\/10.1016\/j.nano.2015.11.017.","journal-title":"Nanomedicine"},{"key":"2770_CR126","doi-asserted-by":"publisher","DOI":"10.1002\/app.43918","author":"BA Aderibigbe","year":"2016","unstructured":"Aderibigbe BA, Mhlwatika Z. Dual release kinetics of antimalarials from soy protein isolate\u2010Carbopol\u2010polyacrylamide based hydrogels. J Appl Polym Sci. 2016. https:\/\/doi.org\/10.1002\/app.43918.","journal-title":"J Appl Polym Sci"},{"issue":"1","key":"2770_CR127","doi-asserted-by":"publisher","DOI":"10.1186\/1556-276X-6-620","volume":"6","author":"P Urb\u00e1n","year":"2011","unstructured":"Urb\u00e1n P, Estelrich J, Adeva A, Cort\u00e9s A, Fern\u00e0ndez-Busquets X. Study of the efficacy of antimalarial drugs delivered inside targeted immunoliposomal nanovectors. Nanoscale Res Lett. 2011;6(1):620. https:\/\/doi.org\/10.1186\/1556-276X-6-620.","journal-title":"Nanoscale Res Lett"}],"container-title":["Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s15010-026-02770-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s15010-026-02770-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s15010-026-02770-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T10:09:50Z","timestamp":1786702190000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s15010-026-02770-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,19]]},"references-count":127,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["2770"],"URL":"https:\/\/doi.org\/10.1007\/s15010-026-02770-6","relation":{},"ISSN":["0300-8126","1439-0973"],"issn-type":[{"value":"0300-8126","type":"print"},{"value":"1439-0973","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,19]]},"assertion":[{"value":"13 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}}]}}